David C B Lye - Infectious Diseases

Author Information

David C. Lye is a prominent researcher affiliated with the Institute of Infectious Diseases and Epidemiology at Tan Tock Seng Hospital in Singapore. His work primarily focuses on infectious diseases, with a substantial contribution to understanding and managing COVID-19. His research interests include antimicrobial stewardship, SARS-CoV-2 infections, and the treatment protocols for COVID-19, showcasing his expertise in both clinical and epidemiological aspects of infectious diseases.

Research Contributions

David C. Lye has made significant contributions to the field of infectious diseases, particularly in the context of the COVID-19 pandemic. Noteworthy among his works are studies on antibiotic therapy in COVID-19 pneumonia, the use of monoclonal antibodies for preventing SARS-CoV-2 infections, and the rapid measurement of SARS-CoV-2 spike T cells. He has also investigated the effects of the COVID-19 pandemic on antimicrobial prevalence and prescribing patterns in Singapore. His research extends to evaluating the capacity for antimicrobial stewardship in the Asia Pacific region and conducting trials on treatment protocols for healthcare-associated infections.

Aliases

David C. Lye is known by several aliases in academic publications, including David C B Lye, D C B Lye, D C Lye, D. C. B. Lye, David Cb Lye, and David Lye. These variations reflect the different ways his name might appear in various databases and publications.

Publication and Citation Metrics

Total Papers	71
Total Citations	2168
H-index	23

Publications:

Antibiotic Therapy in the Treatment of COVID-19 Pneumonia: Who and When?

DOI: 10.3390/antibiotics11020184

Year: 2022

Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections

DOI: 10.1001/jamanetworkopen.2022.5750

Year: 2022

Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals.

DOI: 10.1172/JCI152379

Year: 2021

Effects of coronavirus disease 2019 (COVID-19) pandemic on antimicrobial prevalence and prescribing in a tertiary hospital in Singapore

DOI: 10.1186/s13756-021-00898-8

Year: 2021

Antimicrobial stewardship capacity and manpower needs in the Asia Pacific.

DOI: 10.1016/j.jgar.2021.01.013

Year: 2021

Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial

DOI: 10.1186/s13063-021-05870-w

Year: 2021

Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

DOI: 10.1093/cid/ciab695

Year: 2021

Capacity for antimicrobial stewardship in the Asia Pacific

DOI: 10.1016/j.ijantimicag.2021.106420.22

Year: 2021

A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction

DOI: 10.21203/rs.3.rs-24574/v1

Year: 2020

Age and chest radiography as possible parameters for rapid triage in COVID-19 outbreak surge

DOI: 10.21203/rs.3.rs-88104/v1

Year: 2020

How Does Surveillance Help in Managing Infectious Diseases?

What is the Treatment for E. Coli Infection?

How is Strep Throat Diagnosed?

What is the Global Impact of Rabies?

What are the Long-Term Effects?

How Do Fungi Infect Hosts?

What is the Prognosis for Cervical Cancer?

What Role Does Technology Play in Infectious Disease Education?

Why are Drug Targets Important?

What is MMR?

Partnered Content Networks

Relevant Topics